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The development of particular vector systems for the presentation of immunogenic epitopes provides a powerful approach
for the delivery of antigens. These include the core-like particles formed by recombinant bluetongue virus (BTV) capsid
proteins VP3 and VP7 synthesized in insect cells by recombinant baculoviruses. Previously we have reported localization
of an antigenic site on the surface of tubular structures formed by the nonstructural protein NS1 of BTV, and their potential
use for epitope presentation. In this study foreign sequences ranging from 44 to 116 aa in length and representing 44 aa
sequence from Clostridium difficile toxin A, 48 aa of the hepatitis B virus preS2 region, and the whole of bovine leukemia
virus p15 protein were inserted at the C-terminus of BTV-10 NS1. The chimeric NS1 genes were expressed using recombinant
baculoviruses and the ability of the mutated NS1 proteins to form tubules was investigated. All chimeric constructs formed
tubular structures which carried the foreign antigenic sequences exposed on the surface of the tubules and were highly
immunogenic. When Sf cells were coinfected with three recombinant baculoviruses expressing chimeric NS1 proteins with
different epitopes, their simultaneous assembly into the same tubule was demonstrated. This observation opens up the
possibility of using recombinant NS1 tubules as carriers for the delivery of multiple epitopes. q 1996 Academic Press, Inc.
INTRODUCTION VP7 proteins are synthesised in Spodoptera frugiperda
insect cells by a dual recombinant baculovirus (French
A number of particulate vector systems have been de-
and Roy, 1990). BTV CLPs have been shown to be useful
veloped for the presentation of immunogenic epitopes.
carriers of foreign epitopes by inserting amino acid (aa)
Some systems are based on linking an epitope to a car- sequences originating from rabies virus glycoprotein (11
rier protein capable of assembly into a multimeric partic- aa long, LeBlois and Roy, 1993), or the hepatitis B virus
ulate structure. The particles used to present foreign epi- preS2 region (48 aa long, Belyaev and Roy, 1992), at the
topes include ones formed from hepatitis B surface or amino terminus of the BTV-10 VP7 protein.
core antigens (Clarke et al., 1987), poliovirus (Evans et In addition to the structural components of the virion,
al., 1989), and yeast Ty-particles (Adams et al., 1987). the BTV genome also encodes the nonstructural proteins
Previously we reported the potential of bluetongue vi- NS1, NS2, and NS3/NS3A. A distinctive feature of an
rus (BTV) core-like particles (CLPs), consisting of the orbivirus infection is the formation of numerous tubular
structural proteins VP3 and VP7 (French and Roy, 1990), structures in the cytoplasm of infected cells (Murphy et
for the delivery of foreign epitopes. BTV is the prototype al., 1971). These tubules have a helical conformation and
orbivirus in the family Reoviridae. It is transmitted to ver- a diameter of ca 68 nm as judged by negative staining
tebrates by Culicoides species and may cause an acute (Huismans and Els, 1979). For BTV serotype 10 (BTV-10)
febrile disease in sheep with occasional high mortality. it has been shown that tubules are formed from the 552-
Like other orbiviruses, BTV has a double-stranded RNA amino-acid, 64-kDa NS1 protein encoded by the dsRNA
(dsRNA) genome consisting of 10 segments (L1–3, M4 – segment M6 (Lee and Roy, 1987). When this segment
6, S7–10) located in the core of the virus particle. The was expressed in insect cells by a recombinant baculovi-
core contains two major proteins (VP3 and VP7) and rus, tubular structures of similar morphology were ob-
three minor proteins (VP1, VP4, and VP6) and is sur- served, indicating that no other viral product was involved
rounded by an outer shell consisting of two major pro- in tubule formation (Urakawa and Roy, 1988). Mutational
teins, VP2 and VP5. CLPs are assembled when VP3 and analysis has revealed that the first 10 amino terminal
and 10 or more of the carboxy terminal amino acids
are essential for tubule formation (Monastyrskaya et al.,1 Present address: Rheumatology Department, Academic Hospital,
1994, 1995).Leiden, the Netherlands.
2 To whom reprint requests should be addressed. Analysis of a panel of monoclonal antibodies has es-
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tablished that an NS1 antigenic site is located near to ing sites are underlined. As a result of these manipula-
tions, the NS1 sequence in the pNS1.SpSm vector werethe carboxy terminus of the protein. It appears to be
exposed on the surface of tubules (Monastyrskaya et extended to encode for the following peptide: DPNSTTF
HQTLQDPRVRGLYFPAGGSSSGTVNPVPTTVSPISSIF-al., 1995). Extension mutants including foreign antigenic
sequences involving up to 16 amino acids added to the SRIGD.
C-terminus of NS1 have been shown to form tubules, Similar procedures were employed to amplify the C.
although an extension of 19 amino acids inhibited tubule difficile of toxin A sequence (Wren et al., 1991). The plas-
formation. However, those experiments failed to deter- mid pAcG2T/TOX1 was used as a template for PCR with
mine whether this effect was caused by the size of the the forward primer 5* GGGACTAGTGCAACG-GGCTGG-
inserted epitope or by its particular amino acid sequence. CAGACG 3* and the reverse primer 5* GCGGCCCGGG-
In this study sequences ranging from 44 to 116 aa in GGTGCTAGCAATGGCAGT 3*. By this means, the NS1
length were inserted after the C-terminal amino acid of protein was extended with the following sequence: ATG-
BTV-10 NS1 (Y552). The chimeric NS1 genes were ex- WQTIDGKKYYFNTNTAEAATGWQTIDGKKYYFNTNTA-
pressed using recombinant baculoviruses and the ability IAST.
of the mutated NS1 proteins to form tubules was investi- Similarly, the BLV p15 sequence (Rice et al., 1987) was
gated. These chimeric constructs formed tubular struc- recovered from a plasmid provided by Dr A Burny and
tures which carried the foreign antigenic sequences ex- containing the full-length clone of an integrated form of
posed on the surface of the tubules and were highly BLV (Deschamps et al., 1981). It was initially cloned into
immunogenic. The potential applications of recombinant a pG2T plasmid (Smith and Johnson, 1988) and then re-
NS1 tubules for the delivery of single or multiple epitopes amplified by PCR together with a thrombin cleavage site
are discussed. (LVPRGS) using the forward primer 5* CCCGGACTAGT-
CTGGTTCCGCGTGGATCTAAAATGGCAAATTCC 3* and
the reverse primer 5* CCCGGACTAGTCAAAATGGC-MATERIALS AND METHODS
GGGGGGGTCATAAGG 3*. As there is an internal SmaI
Viruses and cells restriction site in the p15 sequence, both forward and
reverse primers possessed SpeI sites (underlined), andS. frugiperda (Sf) cells were grown in suspension or
the amplified fragment was cloned into pNS1.SpSm di-monolayer cultures at 287C in TC100 medium supple-
gested with SpeI. The sequences corresponding to themented with 10% fetal calf serum. Derivatives of Auto-
N- and C-termini of p15 are shown in italics, and thegrapha californica nuclear polyhedrosis virus (AcNPV)
thrombin cleavage site is highlighted in bold.containing the wild-type BTV-10 NS1 gene (Ac10BTV6)
Vent DNA polymerase (New England Biolabs) wasand the NS1 mutants were plaque purified and propa-
used for the PCR amplifications. The amplified productsgated as described elsewhere (Brown and Faulkner,
were treated with proteinase K, extracted with phenol,1977).
digested with SpeI and SmaI, and purified by GeneClean
as described by the manufacturer (Promega). The mutantExtension mutants of BTV-10 NS1 gene and
sequences were then inserted into the transfer vectorconstruction of recombinant transfer vectors
pNS1.SpSm, generating the recombinant transfer vectors
Polymerase chain reactions (PCR) were employed to pAcNS1.preS2, pAcNS1.ToxA, and pAcNS1.BLVp15. The
amplify the nucleotide sequences encoding a 48-aa hep- sequences at the insertion sites were confirmed by the
atitis B virus (HBV) preS2 region, a 44-aa-long Clostridium dideoxynucleotide technique (Sanger et al., 1977).
difficile toxin A fragment, and the 109-aa bovine leukae-
mia virus (BLV) p15 matrix protein. In all cases the for-
Isolation of recombinant baculovirusesward and reverse primers carried the restriction sites to
enable cloning of the PCR products into a pNS1.SpSm
The lipofection technique (Felgner et al., 1987) wastransfer vector, digested with both SpeI and SmaI, or
used to cotransfect monolayers of Sf cells with recombi-SpeI alone as described previously (Monastyrskaya et
nant transfer vectors and Bsu36I triple-cut AcNPV DNAal., 1995), to provide a C-terminal extension of the BTV-
(Kitts and Possee, 1993). Recombinant baculoviruses10 NS1 protein.
were selected on the basis of their lacZ-negative pheno-To construct the fusion of NS1 with HBV preS2 region,
types, plaque purified, and propagated as describedthe sequence encoding this region was recovered from
elsewhere (King and Possee, 1992). From pAcNS1.preS2the recombinant virus AcBTV7-preS2 (Belyaev and Roy,
transfer vector the recombinant baculovirus AcNS1.preS21992). The following oligonucleotide primers were used:
was obtained. Similarly, from pAcNS1.BLVp15 the recom-the forward primer 5* GCGCACTAGTGATCCGAATTCC-
binant virus AcNS1.BLVp15 was isolated, and from pAcN-ACAACC 3* and the reverse primer 5* GCGCCCCGGG-
ATCCCCAATCCTCGAGAA 3*. The SpeI and SmaI clon- S1.ToxA the recombinant AcNS1.ToxA virus was isolated.
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SDS–polyacrylamide gel electrophoresis (SDS–PAGE) plates were coated overnight with an optimal concen-
tration of antigen (10 mg/well) in carbonate coating
Sf cells were infected with each recombinant baculovi- buffer (15 mM Na2CO3, 36 mM NaHCO3, pH 9.6). Platesrus using a multiplicity of infection (m.o.i.) of 5 plaque were washed once with PBS – 0.05% Tween 20 and
forming units (PFU) per cell (French and Roy, 1990). Cells blocked by covering the wells with PBS supplemented
were harvested at 72 hr postinfection, washed with phos- with 2% (w/v) skimmed milk (50 ml per well). After incu-
phate-buffered saline (PBS), and lysed at 47C in 50 mM bating the plates at 377C for 30 min the wells were
Tris–HCl (pH 8.0), 150 mM NaCl, 0.5% Nonidet P-40. washed three times with PBS – Tween, and serial two-
Protein dissociation buffer (10% (v/v) b-mercaptoethanol, or fivefold dilutions of primary antibody were added for
10% SDS, 25% glycerol, 10 mM Tris–HCl [pH 6.8] and 1 hr at 377C. The plates were then washed five times
0.02% bromphenol blue) was added to each sample and with PBS – Tween and covered with alkaline phospha-
the mixtures heated at 1007C for 10 min. Proteins were tase conjugated secondary antibody (anti-mouse, anti-
resolved by 10 or 15% SDS–PAGE and stained with Coo- rabbit, or anti-human IgG, obtained from Sigma, and
massie brilliant blue. diluted 1:500 in PBS), incubated for 1.5 hr at 377C,
washed as above, and the antigen detected by adding
Purification of tubules
100 ml of substrate per well. The substrate for alkaline
phosphatase was 1 mg/ml of disodium r-nitrophenylBaculovirus-expressed BTV-10 NS1 tubules were puri-
phosphate (pNPP) (Sigma) in 100 mM glycine, 1 mMfied as described previously (Urakawa and Roy, 1988;
MgCl2, 1 mM ZnCl2, pH 10.4. The reaction was left toMonastyrskaya et al., 1994). Sf cells were infected in
develop at 377C for 30 min and then stopped with 3Nsuspension culture with Ac10BTV6 or the various mutant
NaOH and read at 405 nm.NS1 expression vectors using a m.o.i. of 5. After incuba-
tion at 287C for 72 hr, cells were harvested, washed with
Electron microscopyPBS, resuspended in STE buffer (150 mM NaCl, 1 mM
EDTA, 10 mM Tris–HCl, pH 7.5) containing 0.5% (v/v)
NS1 tubules were resuspended in water and absorbedTriton X-100, and lysed by homogenization. The lysate
onto carbon-coated copper 400-mesh EM grids for 2–3was clarified by centrifugation (5 min at 3000 rpm) and
min, washed with water, and negatively stained with 2%the supernatant loaded onto a cushion of 3 ml of 40%
(w/v) uranyl acetate. Grids were examined in a JEOL(w/v) sucrose in STE and centrifuged in a SW41 rotor (2
100CX electron microscope under low-dose conditionshr, 35,000 rpm). The resulting pellet was resuspended in
at 100 kV.a small volume of STE and loaded onto a 10–40% gradi-
For immunogold labeling, grids with absorbed tubulesent of sucrose in STE and centrifuged in a SW28 rotor
were incubated for 5 min in blocking solution containing(1 hr, 20,000 rpm). The pellet and gradient fractions (1.5
0.1% (w/v) BSA in PBS. Grids were then floated on a 1:50ml) of the gradient were collected and the presence of
to 1:200 dilution of an appropriate antibody in blockingNS1 was analyzed by SDS–PAGE.
solution for 1 hr. The grids were then washed three times
with PBS and floated for 1 hr on a solution of a secondaryWestern blot (immunoblot) analysis
antibody (goat anti-rabbit, anti-human, or anti-mouse)
Proteins from gels were transferred onto a nitrocellu- conjugated to 5, 10, or 20 nm colloidal gold particles,
lose membrane by blotting procedures. The membrane respectively, and diluted 1:20 in blocking buffer. The grids
was then soaked in blocking buffer (5% (w/v) skimmed were washed three times in PBS and once in water.
milk, 0.05% Tween 20 in PBS) and incubated for 90 min Sections were stained with uranyl acetate for 10–20 min
in an appropriate antiserum (1:1000 dilution in blocking before viewing in the transmission electron microscope.
buffer). After washing for 30 min in PBS containing 0.05%
Tween 20, the membrane was incubated in blocking RESULTS
buffer containing a 1:1000 dilution of secondary antibody
Construction and expression of chimeric NS1(goat anti-rabbit or anti-mouse) conjugated with alkaline
proteins with foreign epitopes insertedphosphatase. Following a second wash, the membrane
at the C-terminuswas treated with an alkaline phosphatase substrate
(NBT-BCIP from GIBCO-BRL, prepared in 0.1 M Tris–HCl,
The following amino acid sequences were selected
pH 8.5, 0.1 M NaCl, 0.05 M MgCl2r6H2O) for 5 min and for insertion into the C-terminus of BTV-10 NS1: the preS2
then rinsed and dried.
region of hepatitis B virus (48 aa) (Belyaev and Roy, 1992),
an epitope from C. difficile toxin A (44 aa) (Wren et al.,Enzyme-linked immunosorbent assay (ELISA)
1991), and the complete sequence of the BLV matrix
protein p15 (109 aa) (Deschamps et al., 1981). TheseConventional ELISA procedures were performed as
described elsewhere (Gould et al., 1985). MicroELISA sequences were amplified by PCR as described under
AID VY 7740 / 6a11$$$142 02-02-96 10:29:28 viras AP: Virology
326 MIKHAILOV ET AL.
FIG. 1. Expression of mutant NS1 genes in insect cells by recombinant baculoviruses. Extracts of the virus infected Sf cells were separated by
10% SDS–PAGE and stained with Coomassie brilliant blue (a). The resolved products were electroblotted onto nitrocellulose membranes (b, c, d,
and e) and reacted with MAb 10B1 (b), or with anti-toxin A polyclonal antiserum (c), or anti-HBV preS2 antiserum (d), or anti-BLV serum (e), and
the complexes identified as described under Materials and Methods. a, b, c, d, and e show the extracts of Sf cells infected with recombinant
viruses Ac10BTV6 (lane 1), AcNS1.ToxA (lane 2), AcNS1.preS2 (lane 3), and AcNS1.BLVp15 (lane 4).
Materials and Methods using the appropriate forward recombinant NS1 protein, Sf cells were infected with the
appropriate recombinant baculovirus, and cytoplasmicand reverse primers to generate SpeI and SmaI sites
and subsequently cloned into the pNS1.SpSm transfer lysates were obtained and centrifuged in sucrose gradi-
ents, as described under Materials and Methods. Invector (Monastyrskaya et al., 1995). The recombinant
transfer vectors pAcNS1.preS2, pAcNS1.ToxA, and
pAcNS1.BLVp15, which were recovered were then used
to generate the recombinant baculoviruses AcNS1.preS2,
AcNS1.ToxA, and AcNS1.BLVp15.
The expression of chimeric NS1 proteins in infected
cell lysates was analyzed by 10% SDS–PAGE. As shown
in Fig. 1, the expression levels of these proteins were
comparable to that of wild-type BTV NS1. As expected,
their sizes were larger, between 60 kDa (NS1.preS2,
NS1.ToxA) and 65 kDa (NS1.BLVp15) (Fig. 1a, lines 2 to
4) compared to the 56-kDa size observed for wild-type
NS1 (Fig. 1a, lane 1). All the chimeric NS1 proteins were
recognized by the anti-NS1 MAb 10B1 (Fig. 1b) and spe-
cifically recognized by the respective antiserum directed
against the inserted epitope (Fig. 1c for anti-toxin A, 1d for
anti-HBV preS2, and 1e for anti-BLV sera). The NS1.preS2
protein was tested in ELISA with sera obtained from the
HBV-positive humans. The purified NS1.preS2 protein
was absorbed on microELISA plates (approx. 10 mg/well),
and ELISA was performed as described under Materials
and Methods using 16 sera samples. The recombinant
VP7.preS2 protein (Belyaev and Roy, 1992) was used as
positive control, and the wild-type recombinant NS1 was
used as negative control. Fourteen of 16 sera did not
react with the positive control samples, indicating that
these sera lacked detectable antibody titers, and were
therefore excluded from further trials. Two sera (Nos. 8
and 14) showed strong reaction with VP7.preS2 antigen
(Fig. 2). Both sera reacted with the NS1.preS2 protein,
FIG. 2. ELISA analysis of the chimeric NS1.preS2 protein. MicroELISAbut not with the wild-type NS1 (Fig. 2).
plates were coated with the recombinant VP7.preS2 protein (positivePreviously it was demonstrated that in insect cells,
control), wild-type recombinant BTV10 NS1 protein (negative control),
NS1 protein forms tubules which can be recovered as a and the gradient-purified NS1.preS2. All three antigens were then
band by gradient centrifugation (Urakawa and Roy, 1988). tested in ELISA with two sera (serum 8 and serum 14) obtained from
HBV-positive humans using 1:100 to 1:2400 dilutions of sera.In order to examine the tubule-forming capacities of each
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FIG. 3. Immunogold labeling of the chimeric NS1.preS2 tubules using human anti-HBV serum No. 8. Gradient-purified tubules absorbed on EM
grids were reacted with anti-HBV serum and then with the secondary goat anti-human antibody coupled with 10 nm gold particles. The complexes
were visualized by electron microscopy.
each case of the AcNS1.preS2, AcNS1.ToxA, and result obtained for NS1.preS2 chimeric tubules. Similar
AcNS1.BLVp15 mutants the distribution of NS1 protein data were obtained for the NS1.ToxA and NS1.BLVp15
in the fractions was similar to that observed for wild-type constructs (not shown).
NS1. Electron microscopy confirmed that the chimeric Previously it has been demonstrated that the last 5 C-
proteins assembled into tubules which were essentially terminal residues of BTV-10 NS1 protein are not strongly
similar to those formed by wild-type NS1 protein (data involved in tubule formation (Monastyrskaya et al., 1995).
not shown). Taking this observation into account, a coinfection exper-
iment was performed to test whether the three different
Simultaneous assembly of three different chimeric chimeric NS1 proteins with C-terminal extensions would
NS1 proteins into a tubule simultaneously assemble into one tubule. Sf cells were
infected at a m.o.i. of 5 with AcNS1.preS2, AcNS1.ToxA,In order to demonstrate that the foreign sequences
and AcNS1.BLVp15 recombinant baculoviruses, har-are exposed on the surface of the tubules, immunogold
vested 48 hr postinfection, and the NS1 tubules purifiedlabeling experiments were performed as described pre-
following the standard protocol. The tubules obtainedviously (Monastyrskaya et al., 1994). Wild-type NS1 tu-
from single virus infections were used as controls. In allbules, used as a control were not labeled, indicating the
cases tubules were immunogold labeled by incubatingspecificity of the antisera (data not shown). Three differ-
the grids in the mixture of anti-epitope sera (mouse anti-ent sera were used: rabbit anti-BLV antiserum detected
C. difficile toxin A, rabbit anti-BLV, and human anti-HBV),with goat anti-rabbit IgG conjugated with 5 nm gold parti-
and then detected by a mixture of secondary antibodiescles, human anti-HBV antiserum detected with goat anti-
conjugated with gold particles of different sizes. In thehuman IgG conjugated with 10 nm gold, and mouse anti-
control experiments, tubules were labeled only with theC. difficile toxin A serum detected with goat anti-mouse
IgG conjugated with 20 nm gold. Shown in Fig. 3 is the serum specific for the inserted epitope (data not shown).
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FIG. 4. Immunogold labeling of three different chimeric NS1 proteins (NS1.ToxA, NS1.preS2, and NS1.BLVp15) assembled into one tubule. Sf
cells were coinfected with three recombinant baculoviruses, AcNS1.ToxA, AcNS1.preS2, and AcNS1.BLVp15, and tubules were purified by sucrose
gradient centrifugation and reacted on EM grids with the mixture of anti-epitope sera (mouse anti-C. difficile toxin A, rabbit anti-BLV, and human
anti-HBV). The complexes were detected by a mixture of secondary antibodies (goat anti-rabbit, anti-human, and anti-mouse) conjugated to 5 nm
(indicated by thin filled arrow), 10 nm (indicated by white arrow), or 20 nm (indicated by thick filled arrow) colloidal gold particles, respectively.
In the coinfection experiment, the tubules were labeled kDa NS1.BLVp15 protein (Fig. 5, lane 2) was cleaved
with thrombin, and 15-kDa BLV p15 matrix protein waswith gold particles of all three sizes (Fig. 4), indicating
that all three chimeric NS1 proteins were assembled into released from the tubules (Fig. 5, lane 3). The resulting
NS1 tubules was separated by pelleting in a microcentri-the same tubular structure.
fuge (12,000 rpm for 30 min), leaving the p15 protein in
Purification of the tubule-associated BLV p15 matrix the supernatant (Fig. 5, lane 4). These data confirm that
protein by thrombin cleavage the BLV p15 protein is accessible to the enzyme and
gives another indication of the location of the insertedSeveral protein purification systems, for example the
amino acid sequence on the surface of recombinant NS1fusion with glutathione-S-transferase (GST), are based
tubules.on construction of a chimeric protein, one part of which
has an affinity for a particular substrate, such as glutathi-
one. This makes the chimera easy to purify by one-step
affinity chromatography, followed by cleavage of the
fused protein from the agarose-bound GST (Smith and
Johnson, 1988; Davies et al., 1993). A similar approach
was applied to the foreign amino acid sequences fused
with the BTV-10 NS1 protein. As described under Materi-
als and Methods, when constructing the NS1.BLVp15
recombinant, a thrombin cleavage site was introduced
between the C-terminal tyrosine of BTV-NS1 (Y552) and
the BLV p15 matrix protein sequence. In order to test
FIG. 5. Cleavage of NS1.BLVp15 fusion protein analyzed by SDS–whether the site was accessible for cleavage with throm-
PAGE. Lane 1 shows the purified recombinant wild-type NS1; lanebin, approximately 500 mg of purified NS1.BLVp15 tu-
2, purified NS1.BLVp15 fusion protein; lane 3, the thrombin cleavagebules in STE buffer were treated with 5 mg of thrombin
products of NS1.BLVp15, releasing BLV p15 protein from the NS1 tu-
(1 mg/ml solution) in a final volume of 100 ml (4 hr at bules; lane 4, supernatant recovered after centrifugation of the cleavage
room temperature). Figure 5 shows the time course of products (12,000 rpm, 30 min). The molecular weight markers (M) indi-
cated are (top to bottom) 180, 116, 84, 58, 48.5, 36.5, 26.5 kDa.the cleavage, as analyzed by 15% SDS–PAGE. The 65-
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rabbit anti-NS1.ToxA serum was tested for passive inhibi-
tion of enterotoxicity. The assay was performed by mixing
antibody preparations (10 or 30 ml of undiluted rabbit
sera) with 1 mg of toxin A for 1 hr at 377C to allow binding.
The material was then injected into ligated ileal loops of
mice, or rats. The loops were then isolated and weighed
to assay fluid accumulation. It was shown that although
the antibodies failed to prevent fluid accumulation in li-
gated rat loops, when tested in the mouse loops there
was partial inhibition of enterotoxicity (Dr. W. Thomas,
OraVax Inc., personal communication). These data show
that the sera raised against chimeric NS1.ToxA tubules
can provide the protection. The experiments are in prog-
ress to support these observations.
DISCUSSION
Tubule formation is one of the more puzzling aspects
of BTV replication. The functions of BTV tubules and their
constituent NS1 protein are not known, though their as-
sociation with nascent virus particles and the major core
protein VP7 has been observed (Eaton et al., 1988), sug-
gesting that they may be involved in some stages of
BTV morphogenesis. Previously, the studies have been
FIG. 6. ELISA tests of the antisera raised against NS1.BLVp15 and performed, elucidating the structure of the recombinant
NS1.ToxA chimeric proteins. (A) Reaction of antisera raised against tubules and the NS1 sequences required for their poly-
NS1.BLVp15 chimeric protein with BLV antigen in ELISA. The lysate merization. Expressed tubules have been purified and
of mammalian cells infected with bovine leukaemia virus (BLV) was
their biochemical and biophysical properties analyzedabsorbed onto microELISA plates and ELISA was performed using
(Urakawa and Roy, 1988; Marshall et al., 1990). Threerabbit serum raised against the recombinant NS1.BLVp15 with and
without (w.a.) adjuvant, and anti-BTV-10 NS1 antiserum, as indicated dimensional studies of tubules using cryoelectron mi-
in the figure and using 1:400 to 1:3200 dilutions of sera. (B) Reaction croscopy and image processing techniques have shown
of antisera raised against NS1.ToxA chimeric protein with C. difficile that they are some 52.3 nm in diameter and composed
toxin A in ELISA. Rabbit serum was obtained following standard proto-
of a coiled ribbon of dimers with ca. 22 dimers per turn.cols and used in 1:400 to 1:6400 dilution. Anti-BTV-10 NS1 serum was
Each NS1 subunit has a diameter of ca. 5.3 nm (Hewatused as a control.
et al., 1992).
The BTV-10 NS1 protein has a low content of charged
The antigenicity of chimeric NS1 proteins
amino acids but is rich in cysteines, suggesting that it
has a highly ordered structure (Roy et al., 1990). Muta-To determine whether the chimeric NS1 tubules were
biologically active, the immunogenicities of the struc- tional analyses of the BTV-10 NS1 gene have revealed
the importance of certain cysteine residues for tubuletures were assessed. Rabbit polyclonal antisera against
NS1.ToxA and NS1.BLVp15 were prepared following formation (e.g., C337 and C340), as well as the amino
and carboxy termini of the protein (Monastyrskaya et al.,standard protocols. Three rabbits were immunized with
the purified chimeric NS1 tubules (1 mg each), boosted 1994).
In a previous study, short amino acids sequencesafter 21 days, and the sera subsequently recovered and
assayed in ELISA with native Clostridium toxin A or BLV were added to the NS1 C-terminus to create a new
type of a particulate vector system for the delivery ofantigen (with and without adjuvant). The results of ELISA
for all sera are shown in Fig. 6. The anti-NS1.BLVp15 antigens. However, the failure of a longer extension
mutant to form tubules raised the question of whethersera gave titers of 1:3200 (Fig. 6A), whereas the anti-
NS1.ToxA serum gave titers of at least 1:6400 (Fig. 6B). it was the size or the sequence of the addition that
caused this effect (Monastyrskaya et al., 1995). In theThe particulate nature and size of NS1 tubules (68 nm
in diameter and up to 1000 nm long as judged by electron study reported here we have demonstrated that two
longer sequences (a 44-aa C. difficile toxin A sequencemicroscopy) has prompted us to undertake immuniza-
tions without adjuvant using NS1.BLVp15. The resulting and a 48-aa HBV preS2 sequence), as well as the 109-
aa BLV p15 matrix protein sequence inserted at the C-sera titers were comparable to those obtained using
standard protocols (Fig. 6A). In preliminary studies, the terminus of BTV-10 NS1, allowed the formation of tubu-
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lar structures. In contrast, insertion of the similarly cells (Urakawa and Roy, 1988)), tubules are easy to purify,
and so they could provide an efficient and inexpensivesized 48-aa-long HIV V3 loop (Kim et al., 1995; Doyle
et al., 1995) prevented tubule formation and only aggre- system for the presentation of single or multiple foreign
epitopes.gated protein was produced (unpublished observa-
tion). The HIV sequence is known to form a loop struc-
ture involving a cysteine bridge. Whether the HIV V3 ACKNOWLEDGMENTS
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